Published in Cancer Weekly, January 9th, 2007
The open-label, multicenter international trial was designed to examine the efficacy and safety of Sprycel at 70 mg twice daily or an increased dose of Gleevec to 800 mg/day (patients enrolled in the trial had been previously treated with Gleevec less than or equal to 600 mg/day). Results were presented at the 48th Annual Meeting and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.